Correlation between miR-200 Family Overexpression and Cancer Prognosis

Table 1

Main characteristics of the eligible studies.

First author	Year	Country	Age	Cancer type	MicroRNA	Sample size	Follow-up, median (range)	Outcome
Zou J. [16]	2017	China	NA	EOC	miR-429	72	NA	OS/PFS
Han Y. [17]	2017	China	NA	CRC	miR-429	71	34.2	OS
Maierthaler M. [18]	2017	Germany	70 (33–92); 68.0 (36–92)	CRC	miR-200a, miR-200b, miR-200c, miR-141, miR-429	527	NA	OS/RFS
Si L. [19]	2017	China	60.5 (41–78)	NSCLC	miR-200c	110	NA	OS/DFS
Meng X. [20]	2016	Germany	60 (23–91)	EOC	miR-200a, miR-200b, miR-200c	163	20 (1–136)	OS/RFS
Dong S. J. [21]	2016	China	56 (31–79)	CRC	miR-429	116	NA	OS
Antolín S. [22]	2015	Spain	54.8 (29–73)	BC	miR-200c, miR-141	57	74.6 (74.2–77.7)	OS/PFS
Gao Y. C. [23]	2015	China	NA	EOC	miR-200c, miR-141	93	NA	OS
Lu Y. B. [24]	2015	China	NA	GC	miR-141	95	NA	OS
Liu J. Y. [25]	2015	China	57.48	EOC	miR-200a	44	26 (5–49)	OS/PFS
Cao Q. [26]	2014	China	58 (26–88)	EOC	miR-200a, miR-200b, miR-200c	100	36.8 (6–56)	OS
Kim M. K. [27]	2014	Korea	64 (26–77)	NSCLC	miR-200c	72	31 (1–135)	OS
Zhu W. [28]	2014	China	59	NSCLC	miR-429	70	NA	OS
Song F. [29]	2014	China	60.5	GC	miR-200a, miR-200b, miR-200c	385	35 (1–112)	OS/PFS
Tejero R. [30]	2014	Spain	65 (35–85)	NSCLC	miR-200c/141	155	43 (2–160)	OS
Toiyama Y. [31]	2014	Japan	67	CRC	miR-200c	182	NA	OS
Sun Q. [32]	2014	China	NA	EOC	miR-200a	53	56.79 (11–98)	OS
Liu X. G. [33]	2012	China	NA	NSCLC	miR-200c, miR-141	70	24	OS
Chao A. [34]	2012	China	NA	EOC	miR-200a	176	40 (3–109)	OS/RFS
Marchini S. [35]	2011	Italy	52 (21–82)	EOC	miR-200b, miR-200c	144	110.4 (82.8–139.2)	OS/PFS
Cheng H. [36]	2011	USA	NA	CRC	miR-141	156	NA	OS
Leskelä S. [37]	2010	Spain	57 (35–85)	EOC	miR-200a, miR-200b, miR-200c, miR-141, miR-429	72	NA	OS/PFS/RFS
Hu X. [38]	2009	USA	58.3	EOC	miR-200a	55	NA	OS/PFS

NA: not available; EOC: epithelial ovarian cancer; BC: breast cancer; NSCLC: nonsmall cell lung cancer; GC: gastric cancer; CRC: colorectal cancer; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; RFS: recurrence- or relapse-free survival; : hazard ratio; CI: confidence interval.